Oncologix Tech (OCLG) Ratios
Oncologix Tech Ratios
OCLG's free cash flow for Q1 2023 was $-18.77K. For the 2023 fiscal year, OCLG's free cash flow was increased by $0.00 and operating cash flow was $-18.77K. See a summary of the company’s cash flow.
| Ratios | Aug 17 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 0.03 |
| Quick Ratio | 0.03 |
| Cash Ratio | 0.00 |
| Solvency Ratio | -0.32 |
| Operating Cash Flow Ratio | -0.00 |
| Short-Term Operating Cash Flow Coverage | -0.00 |
| Net Current Asset Value | $ -7.22M |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 3.45 |
| Debt-to-Equity Ratio | -0.86 |
| Debt-to-Capital Ratio | -6.33 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | -0.25 |
| Debt Service Coverage Ratio | -0.17 |
| Interest Coverage Ratio | -0.69 |
| Debt to Market Cap | 23.33 |
| Interest Debt Per Share | 0.01 |
| Net Debt to EBITDA | -4.62 |
| Profitability Margins | |
| Gross Profit Margin | 20.05% |
| EBIT Margin | -39.47% |
| EBITDA Margin | -38.95% |
| Operating Profit Margin | -30.35% |
| Pretax Profit Margin | -83.19% |
| Net Profit Margin | -83.19% |
| Continuous Operations Profit Margin | -83.19% |
| Net Income Per EBT | 100.00% |
| EBT Per EBIT | 274.10% |
| Return on Assets (ROA) | -158.58% |
| Return on Equity (ROE) | 39.71% |
| Return on Capital Employed (ROCE) | 14.49% |
| Return on Invested Capital (ROIC) | 106.15% |
| Return on Tangible Assets | 265.79% |
| Earnings Yield | -1072.92% |
| Efficiency Ratios | |
| Receivables Turnover | 13.60 |
| Payables Turnover | 1.90 |
| Inventory Turnover | 759.67 |
| Fixed Asset Turnover | 205.52 |
| Asset Turnover | 1.91 |
| Working Capital Turnover Ratio | -0.48 |
| Cash Conversion Cycle | -165.12 |
| Days of Sales Outstanding | 26.84 |
| Days of Inventory Outstanding | 0.48 |
| Days of Payables Outstanding | 192.44 |
| Operating Cycle | 27.32 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -0.00 |
| Free Cash Flow Per Share | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -26.51 |
| Capital Expenditure Coverage Ratio | -26.51 |
| Operating Cash Flow Coverage Ratio | -0.00 |
| Operating Cash Flow to Sales Ratio | -0.01 |
| Free Cash Flow Yield | -11.37% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -0.09 |
| Price-to-Sales (P/S) Ratio | 0.08 |
| Price-to-Book (P/B) Ratio | -0.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.80 |
| Price-to-Operating Cash Flow Ratio | -9.13 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 |
| Enterprise Value Multiple | -4.82 |
| Enterprise Value | 5.35M |
| EV to EBITDA | -4.82 |
| EV to Sales | 1.88 |
| EV to Free Cash Flow | -212.82 |
| EV to Operating Cash Flow | -220.85 |
| Tangible Book Value Per Share | -0.01 |
| Shareholders’ Equity Per Share | -0.01 |
| Tax and Other Ratios | |
| Effective Tax Rate | -0.00 |
| Revenue Per Share | 0.00 |
| Net Income Per Share | -0.00 |
| Tax Burden | 1.00 |
| Interest Burden | 2.11 |
| Research & Development to Revenue | 0.00 |
| SG&A to Revenue | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 |
| Income Quality | 0.01 |
Currency in USD
